MX2022007527A - Inhibidores de proteinas kras mutantes. - Google Patents
Inhibidores de proteinas kras mutantes.Info
- Publication number
- MX2022007527A MX2022007527A MX2022007527A MX2022007527A MX2022007527A MX 2022007527 A MX2022007527 A MX 2022007527A MX 2022007527 A MX2022007527 A MX 2022007527A MX 2022007527 A MX2022007527 A MX 2022007527A MX 2022007527 A MX2022007527 A MX 2022007527A
- Authority
- MX
- Mexico
- Prior art keywords
- mutant protein
- kras mutant
- protein inhibitors
- kras
- inhibitor
- Prior art date
Links
- 102000008300 Mutant Proteins Human genes 0.000 title abstract 2
- 108010021466 Mutant Proteins Proteins 0.000 title abstract 2
- 229940121649 protein inhibitor Drugs 0.000 title abstract 2
- 239000012268 protein inhibitor Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a un inhibidor de la proteína KRAS mutante mostrado como fórmula(I), una composición que contiene el inhibidor y su uso. (ver Fórmula).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019126687 | 2019-12-19 | ||
| CN2020070885 | 2020-01-08 | ||
| CN2020073723 | 2020-01-22 | ||
| CN2020078565 | 2020-03-10 | ||
| PCT/CN2020/137497 WO2021121367A1 (en) | 2019-12-19 | 2020-12-18 | Kras mutant protein inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007527A true MX2022007527A (es) | 2022-07-19 |
Family
ID=76478185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007527A MX2022007527A (es) | 2019-12-19 | 2020-12-18 | Inhibidores de proteinas kras mutantes. |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11180506B2 (es) |
| EP (1) | EP4077326A4 (es) |
| JP (1) | JP2023506532A (es) |
| KR (1) | KR20220119088A (es) |
| CN (4) | CN113651814B (es) |
| AU (1) | AU2020404319A1 (es) |
| BR (1) | BR112022011421A2 (es) |
| CA (1) | CA3165238A1 (es) |
| CL (1) | CL2022001670A1 (es) |
| CO (1) | CO2022010098A2 (es) |
| CR (1) | CR20220351A (es) |
| IL (1) | IL293962A (es) |
| MX (1) | MX2022007527A (es) |
| PE (1) | PE20230161A1 (es) |
| TW (1) | TW202128691A (es) |
| WO (1) | WO2021121367A1 (es) |
| ZA (2) | ZA202207450B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP3871673B1 (en) | 2018-10-26 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | Novel indazole compound or salt thereof |
| JP2022517222A (ja) | 2019-01-10 | 2022-03-07 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| CN111484477B (zh) * | 2019-01-29 | 2022-07-08 | 博瑞生物医药（苏州）股份有限公司 | 一种苯并吡啶酮杂环化合物及其用途 |
| WO2021041671A1 (en) | 2019-08-29 | 2021-03-04 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| MX2022003537A (es) | 2019-09-24 | 2022-07-11 | Mirati Therapeutics Inc | Terapias de combinacion. |
| BR112022007783A8 (pt) | 2019-10-28 | 2023-04-11 | Merck Sharp & Dohme | Composto, composição farmacêutica, e, métodos para inibir proteína g12c de kras e para tratar câncer |
| CN118059104A (zh) | 2019-12-19 | 2024-05-24 | 阿尔维纳斯运营股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
| IL293962A (en) * | 2019-12-19 | 2022-08-01 | Jacobio Pharmaceuticals Co Ltd | Mutant kras protein inhibitors |
| KR20220130126A (ko) | 2019-12-20 | 2022-09-26 | 미라티 테라퓨틱스, 인크. | Sos1 억제제 |
| CN114671866A (zh) * | 2020-12-25 | 2022-06-28 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| WO2021249563A1 (zh) * | 2020-06-12 | 2021-12-16 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
| CN116457358A (zh) | 2020-09-15 | 2023-07-18 | 锐新医药公司 | 作为ras抑制剂以治疗癌症的吲哚衍生物 |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| JP2024517845A (ja) | 2021-05-05 | 2024-04-23 | レボリューション メディシンズ インコーポレイテッド | がん治療のためのｒａｓ阻害剤 |
| WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
| CN117295742A (zh) * | 2021-05-12 | 2023-12-26 | 北京加科思新药研发有限公司 | 化合物ⅰ的新形式及它们的应用 |
| MX2024000965A (es) | 2021-07-27 | 2024-02-09 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
| CN115894520A (zh) * | 2021-09-23 | 2023-04-04 | 上海和誉生物医药科技有限公司 | 一种大环k-ras g12c抑制剂及其制备方法和在药学上的应用 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| WO2024102421A2 (en) | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| US20240352038A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| US20240352036A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3519402A1 (en) * | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2018140600A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| JOP20190272A1 (ar) * | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| US10689377B2 (en) * | 2017-11-15 | 2020-06-23 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| EP3741756B1 (en) * | 2018-01-19 | 2023-11-01 | Medshine Discovery Inc. | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
| EP4268898A3 (en) * | 2018-06-11 | 2024-01-17 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
| JP7369719B2 (ja) | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法 |
| IL293962A (en) * | 2019-12-19 | 2022-08-01 | Jacobio Pharmaceuticals Co Ltd | Mutant kras protein inhibitors |
-
2020
- 2020-12-18 IL IL293962A patent/IL293962A/en unknown
- 2020-12-18 AU AU2020404319A patent/AU2020404319A1/en active Pending
- 2020-12-18 CN CN202111058976.0A patent/CN113651814B/zh active Active
- 2020-12-18 WO PCT/CN2020/137497 patent/WO2021121367A1/en active Application Filing
- 2020-12-18 CA CA3165238A patent/CA3165238A1/en active Pending
- 2020-12-18 JP JP2022537297A patent/JP2023506532A/ja active Pending
- 2020-12-18 CN CN202210597916.4A patent/CN115192577B/zh active Active
- 2020-12-18 TW TW109145045A patent/TW202128691A/zh unknown
- 2020-12-18 EP EP20903388.5A patent/EP4077326A4/en active Pending
- 2020-12-18 BR BR112022011421A patent/BR112022011421A2/pt unknown
- 2020-12-18 CN CN202111617953.9A patent/CN114349750A/zh active Pending
- 2020-12-18 KR KR1020227024638A patent/KR20220119088A/ko unknown
- 2020-12-18 PE PE2022001137A patent/PE20230161A1/es unknown
- 2020-12-18 CR CR20220351A patent/CR20220351A/es unknown
- 2020-12-18 CN CN202080014581.8A patent/CN113454083A/zh active Pending
- 2020-12-18 MX MX2022007527A patent/MX2022007527A/es unknown
-
2021
- 2021-03-10 US US17/197,095 patent/US11180506B2/en active Active
- 2021-08-20 US US17/407,418 patent/US11787811B2/en active Active
- 2021-12-27 US US17/562,492 patent/US20220213109A1/en active Pending
-
2022
- 2022-06-17 CL CL2022001670A patent/CL2022001670A1/es unknown
- 2022-07-05 ZA ZA2022/07450A patent/ZA202207450B/en unknown
- 2022-07-18 CO CONC2022/0010098A patent/CO2022010098A2/es unknown
- 2022-08-05 ZA ZA2022/08783A patent/ZA202208783B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220119088A (ko) | 2022-08-26 |
| CO2022010098A2 (es) | 2022-10-11 |
| US11787811B2 (en) | 2023-10-17 |
| EP4077326A4 (en) | 2024-04-24 |
| IL293962A (en) | 2022-08-01 |
| ZA202208783B (en) | 2024-01-31 |
| EP4077326A1 (en) | 2022-10-26 |
| US20210292331A1 (en) | 2021-09-23 |
| PE20230161A1 (es) | 2023-02-01 |
| CR20220351A (es) | 2022-10-31 |
| CN115192577B (zh) | 2024-03-29 |
| US20230011726A1 (en) | 2023-01-12 |
| TW202128691A (zh) | 2021-08-01 |
| US20220213109A1 (en) | 2022-07-07 |
| CN113651814A (zh) | 2021-11-16 |
| CL2022001670A1 (es) | 2023-03-17 |
| ZA202207450B (en) | 2023-04-26 |
| JP2023506532A (ja) | 2023-02-16 |
| CN113454083A (zh) | 2021-09-28 |
| WO2021121367A1 (en) | 2021-06-24 |
| BR112022011421A2 (pt) | 2022-08-30 |
| US11180506B2 (en) | 2021-11-23 |
| AU2020404319A1 (en) | 2022-08-18 |
| CA3165238A1 (en) | 2021-06-24 |
| CN115192577A (zh) | 2022-10-18 |
| CN114349750A (zh) | 2022-04-15 |
| CN113651814B (zh) | 2022-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007527A (es) | Inhibidores de proteinas kras mutantes. | |
| MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| MX2021014443A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
| MX2022002465A (es) | Inhibidores de kras g12d. | |
| MX2023008031A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| MX2021004245A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
| ZA202213566B (en) | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| PH12020500655A1 (en) | Compounds | |
| EP4167993A4 (en) | 5-OXOPYRROLIDINE-3-CARBOXAMIDE AS NAV1.8 INHIBITORS | |
| EP4167994A4 (en) | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDE AS NAV1.8 INHIBITORS | |
| MX2020009234A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. | |
| MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
| MX2022007841A (es) | Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos. | |
| MX2017015357A (es) | Compuestos inhibidores de serina/treonina-proteina cinasa (tbk)/inhibidor de cinasa de factor nuclear kappa-b subunidad epsilon (ikk-epsilon) y usos de los mismos. | |
| MX2022001004A (es) | Inhibidores de enzimas. | |
| MX2021003843A (es) | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. | |
| ZA202202245B (en) | Quinoline derivatives as protein kinase inhibitors | |
| MX2022006750A (es) | Inhibidores de masp-2 y metodos de uso. | |
| CR20220252A (es) | Nuevos inhibidores de braf como rompedores de la paradoja | |
| MX2022000811A (es) | Inhibidores de enzimas. | |
| MY193239A (en) | Novel b-lactamase inhibitors | |
| CR20210614A (es) | Nuevos inhibidores de egfr | |
| MX2022006312A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. |